What is Biorelate?
Biorelate specializes in advanced data curation technology tailored for the biopharmaceutical industry. Their core offering, Galactic AI, is a comprehensive knowledge graph designed to assist bioinformatics professionals in identifying and validating new drug targets, understanding mechanisms of action, and exploring complex target-drug-disease relationships. By connecting causal insights from a multitude of sources, Biorelate's platform streamlines the research process for clients ranging from multinational pharmaceutical giants like Pfizer and AstraZeneca to emerging biotech firms. The company's technology empowers clients to accelerate discovery timelines and enhance strategic decision-making in the critical field of drug development.
How much funding has Biorelate raised?
Biorelate has raised a total of $6.5M across 1 funding round:
Series A
$6.5M
Series A (2022): $6.5M with participation from YFM Equity Partners, Manchester Technology Fund, Maven Capital Partners UK, and Triple Point Ventures
Key Investors in Biorelate
YFM Equity Partners
YFM Equity Partners is a private equity firm based in the United Kingdom, established in 2001, that supports project development and offers coaching for entrepreneurs in business establishment.
Manchester Technology Fund
The Manchester Technology Fund is a £6 million investment fund exclusively focused on the University of Manchester, providing early-stage equity funding for spin-out companies across various technologies, including IT and Life Sciences.
Maven Capital Partners UK
Maven Capital Partners UK LLP operates within the Venture Capital & Private Equity sector, providing investment and advisory services to businesses.
What's next for Biorelate?
The substantial enterprise-level backing positions Biorelate for significant expansion and further innovation in its data curation and AI-driven drug discovery solutions. This strategic investment is expected to fuel the enhancement of its Galactic AI platform, potentially broadening its market reach and deepening its integration with key industry players. Biorelate is poised to further solidify its position as a leader in providing critical data intelligence for biopharmaceutical research, aiming to accelerate the development of novel therapeutics and improve patient outcomes.
See full Biorelate company page
